Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6269870 | 0.84 | KMT2A (0.55) | KMT2AMEN1KDM4EMAPTPABPC1 | |
| SCHEMBL8349276 | 0.80 | KMT2A (0.53) | KMT2AMEN1KDM4EMAPTPABPC1 | |
| SCHEMBL3212183 | 0.80 | MEN1 (0.50) | KMT2AMEN1KDM4EMAPTPABPC1 | |
| SCHEMBL18171768 | 0.79 | KMT2A (0.49) | KMT2AMEN1KDM4EMAPTPABPC1 | |
| SCHEMBL12933403 | 0.77 | KMT2A (0.50) | KMT2AMEN1KDM4EMAPTPABPC1 | |
| SCHEMBL25650053 | 0.77 | STK17A (0.42) | MAPTHDAC1HDAC8HDAC6NPSR1 | |
| SCHEMBL4459452 | 0.76 | KMT2A (0.57) | KMT2AMEN1KDM4EMAPTPABPC1 | |
| SCHEMBL31363149 | 0.76 | KMT2A (0.49) | KMT2AMEN1KDM4EMAPTPABPC1 | |
| SCHEMBL8348534 | 0.76 | KMT2A (0.49) | KMT2AMEN1KDM4EMAPTPABPC1 | |
| SCHEMBL31252505 | 0.76 | KMT2A (0.51) | KMT2AMEN1KDM4EMAPTPABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008100622-A2 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-20220144818-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020210308-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008100622-A2 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-0796847-B1 | Pyridine derivative, anti-ulcer drug, and antibacterial drug | SHISEIDO CO LTD (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-6017937-A | BACTERICIDE AGAINST HELICOBACTER PYROLI; INHIBITING ACID SECRETION IN STOMACH OF MAN OR MAMMALS, PREVENTING OR CURING ULCER | SHISEIDO CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| US-5859032-A | HAVING ANTIBACTERIAL ACTIVITY AGAINST HELICOBACTER PYLORI | SHISEIDO CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0796847-A1 | Pyridine derivative, anti-ulcer drug, and antibacterial drug | SHISEIDO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144818-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS3BP, LGALS1 | KMT2A 4596/4885MEN1 2349/4885KDM4E 3889/4885 |
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | KMT2A 4149/4885MEN1 4873/4885KDM4E 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.